3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Colorectal Neoplasms
10
Neoplasm Metastasis
4
Lung Neoplasms
4
Colonic Neoplasms
4
Neoplasms
3
Pancreatic Neoplasms
2
Carcinoma, Renal Cell
2
Solid Tumors
1
Resectable Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Kidney Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
Capecitabine
41
Oxaliplatin
39
Fluorouracil
29
Leucovorin
23
Radiotherapy
21
Cetuximab
14
Bevacizumab
14
Irinotecan
13
Nivolumab
12
Magnetic Resonance Spectroscopy
11
Specimen Handling
9
Surgical Procedures, Operative
8
Folfox protocol
8
Drug Therapy
8
pembrolizumab
7
Radiotherapy, Intensity-Modulated
7
Chemoradiotherapy
7
Biopsy
7
trifluridine tipiracil drug combination
6
Radiation
6
tislelizumab
5
sintilimab
5
regorafenib
5
dehydroftorafur
5
X-Rays
5
Surveys and Questionnaires
5
Sigmoidoscopy
5
Endoscopy
5
Consolidation Chemotherapy
5
spartalizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rectal Neoplasms
×
adagrasib
×
1 year
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled